Financial Data and Key Metrics Changes - The company reported net operating revenues of $21.3 billion for 2025, with consolidated adjusted EBITDA of $4.57 billion, representing a 14% growth over 2024 [5][13] - The adjusted EBITDA margin for the full year was 21.4%, an improvement of 210 basis points from the prior year [14] - In Q4 2025, total net operating revenues were $5.5 billion, with consolidated adjusted EBITDA of $1.183 billion, a 13% increase year-over-year [12] Business Line Data and Key Metrics Changes - The USPI segment's adjusted EBITDA grew 12% in 2025 to $2.026 billion, with same-facility revenues increasing by 7.2% [6][14] - The hospital segment's adjusted EBITDA increased by 16% to $2.54 billion, with same-store revenues per adjusted admission up 5.3% [7][14] - Same facility revenues grew 7.5%, driven by double-digit growth in total joint replacements in ASCs [7] Market Data and Key Metrics Changes - The company experienced strong same-store revenue growth, exceeding the long-term goal of 3%-6% organic growth [7] - The company anticipates a 20% reduction in overall enrollment due to the expiration of enhanced premium tax credits, which may impact the hospital segment significantly [10][11] Company Strategy and Development Direction - The company plans to continue focusing on organic growth supplemented by accretive M&A, particularly in the USPI segment, with a target of $250 million in annual M&A [8][22] - The company is also investing in technology and operational efficiencies to enhance expense management and improve clinical throughput [28][45] - The company aims to leverage its capabilities to serve patients better and expand service lines, particularly in high acuity areas [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong core earnings growth for 2026, despite anticipated headwinds from the expiration of enhanced premium tax credits [11][19] - The company expects adjusted EBITDA for 2026 to be in the range of $4.485 billion to $4.785 billion, driven by ongoing demand and acuity [9][18] - Management highlighted the importance of monitoring enrollment levels and effectuation rates as they navigate the changing healthcare landscape [11][72] Other Important Information - The company repurchased approximately 22% of its outstanding shares for around $2.5 billion since the share repurchase program began in Q4 2022 [8] - The company generated $367 million of free cash flow in Q4 2025, totaling $2.53 billion for the full year [15] Q&A Session Summary Question: Can you expand on the same-store hospital volume performance in the quarter? - Management noted that while acuity was good, the respiratory season was weaker than expected, impacting volumes [25] Question: What do you mean by tackling expense management more structurally? - Management explained that they are focusing on technology deployment for sustainable expense reduction, including automation and clinical throughput improvements [27][28] Question: Can you provide more details on the hospital admission growth guidance of 1%-2%? - Management indicated that the guidance reflects anticipated impacts from exchange exposure and investments in higher acuity capabilities [32] Question: Is the growth type sustainable in future years? - Management believes that while achieving 10% growth is ambitious, their track record of acuity growth and margin expansion supports this outlook [39][40] Question: What is the payer mix for USPI in Q4? - Management reported a consistent payer mix with net revenue per case growth of 5.5% and EBITDA margins above 40% [84]

Financial Data and Key Metrics Changes - The company reported net operating revenues of $21.3 billion for 2025, with consolidated Adjusted EBITDA of $4.57 billion, representing a 14% growth over 2024 [5][13] - The full-year Adjusted EBITDA margin improved by 200 basis points to 21.4% compared to the prior year [5][14] - In Q4 2025, total net operating revenues were $5.5 billion, with consolidated Adjusted EBITDA of $1.183 billion, a 13% increase year-over-year [12][13] Business Line Data and Key Metrics Changes - The USPI segment's Adjusted EBITDA grew 12% in 2025 to $2.026 billion, with same-facility revenues increasing by 7.2% [6][14] - The hospital segment's Adjusted EBITDA increased by 16% to $2.54 billion, with same-store revenues per adjusted admission up 5.3% [7][14] - Same facility revenues grew 7.5%, driven by double-digit growth in total joint replacements in ASCs [7] Market Data and Key Metrics Changes - The company experienced strong same-store revenue growth, exceeding the long-term goal of 3%-6% organic growth [7] - In Q4, exchange volumes accounted for approximately 7.5% of total admissions and over 6% of consolidated revenues [69] Company Strategy and Development Direction - The company plans to continue focusing on organic growth supplemented by M&A, with nearly $350 million invested in 2025 and 35 facilities added to the portfolio [7][8] - The company expects to tackle expense management more structurally, leveraging technology for sustainable cost reductions [27][28] - The company anticipates a gradual tailwind from the phase-out of the Inpatient Only List starting in 2026, with opportunities in high acuity procedures [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong core earnings growth for 2026, despite anticipated headwinds from the expiration of enhanced premium tax credits [11][19] - The company expects full-year 2026 Adjusted EBITDA in the range of $4.485 billion to $4.785 billion, driven by ongoing demand strength and service line expansion [9][18] - Management acknowledged uncertainty regarding enrollment levels and effectuation rates, which could impact future performance [11][19] Other Important Information - The company repurchased approximately 22% of its outstanding shares for around $2.5 billion since the share repurchase program began in Q4 2022 [8][16] - The company generated $2.53 billion of free cash flow for the full year 2025, with $2.8 billion in cash on hand as of December 31, 2025 [15][16] Q&A Session Summary Question: Can you expand on the same-store hospital volume performance in the quarter? - Management noted that while acuity was good, the respiratory season was weaker than expected, impacting volumes [25] Question: What do you mean by tackling expense management more structurally? - Management explained that they are focusing on technology deployment for sustainable expense reductions, moving beyond traditional annual expense management [27][28] Question: Can you provide more details on the hospital admission growth guidance of 1%-2%? - Management indicated that the guidance reflects anticipated impacts from exchange exposure and investments in higher acuity capabilities [32] Question: Is the growth expected to be sustainable in future years? - Management expressed confidence in the sustainability of growth, citing a track record of acuity and revenue per case growth [39][40] Question: What is the payer mix for USPI in Q4? - Management reported a consistent payer mix, with net revenue per case growth of 5.5% and EBITDA margins above 40% [83]

Financial Data and Key Metrics Changes - Tenet Healthcare reported net operating revenues of $21.3 billion for 2025, with consolidated adjusted EBITDA of $4.57 billion, reflecting a 14% growth over 2024 [4][11] - The full-year adjusted EBITDA margin improved by 200 basis points to 21.4% compared to the prior year [4][12] - In Q4 2025, total net operating revenues were $5.5 billion, with consolidated adjusted EBITDA of $1.183 billion, a 13% increase year-over-year [11][12] Business Line Data and Key Metrics Changes - The USPI segment's adjusted EBITDA grew 12% in 2025 to $2.026 billion, with same-facility revenues increasing by 7.2% [4][12] - The hospital segment's adjusted EBITDA rose 16% to $2.54 billion, with same-store revenues per adjusted admission up 5.3% [5][12] - Same facility revenues in the ASCs grew by 7.5%, driven by double-digit growth in total joint replacements [5] Market Data and Key Metrics Changes - The company anticipates a 20% reduction in overall enrollment due to the expiration of enhanced premium tax credits, particularly affecting states like Arizona, Michigan, and California [9][10] - In Q4, exchange admissions accounted for approximately 7.5% of total admissions, contributing over 6% to consolidated revenues [68] Company Strategy and Development Direction - Tenet plans to continue focusing on organic growth supplemented by M&A, with nearly $350 million invested in 2025 and 35 facilities added to the portfolio [5][6] - The company is tackling expense management more structurally, leveraging technology for sustainable cost reductions [25][26] - The strategic focus includes expanding service lines and enhancing capabilities in high-acuity procedures, particularly in the USPI segment [8][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong core earnings growth for 2026, despite anticipated headwinds from the expiration of enhanced tax credits [10][14] - The company expects adjusted EBITDA for 2026 to be in the range of $4.485 billion to $4.785 billion, driven by ongoing demand and acuity [7][16] - Management highlighted the importance of monitoring enrollment levels and effectuation rates as they impact future performance [10][81] Other Important Information - Tenet has been active in share repurchases, retiring approximately 22% of outstanding shares for around $2.5 billion since Q4 2022 [6][14] - The company generated $2.53 billion of free cash flow for the full year 2025, with $2.8 billion in cash on hand as of December 31, 2025 [13][14] Q&A Session Summary Question: Can you expand on the same-store hospital volume performance in the quarter? - Management noted that while acuity was good, the respiratory season was weaker than expected, impacting volumes [23] Question: What do you mean by tackling expense management more structurally? - Management explained that they are focusing on technology deployment for sustainable expense reductions, moving beyond traditional annual management [25][26] Question: Can you clarify the hospital admission growth guidance of 1%-2%? - Management indicated that the guidance reflects anticipated impacts from exchange enrollment reductions and investments in higher acuity capabilities [30][31] Question: What is the payer mix for USPI in Q4? - Management reported a consistent payer mix, with net revenue per case growth of 5.5% and EBITDA margins above 40% [83]

4th Quarter 2025 Earnings Release Presentation February 11, 2026 Cautionary Statements This presentation includes "forward looking statements." These statements relate to future events, including, but not limited to, statements regarding our liquidity, operating results, future earnings, financial position, operational and strategic initiatives, and developments in legislation, regulation, and the healthcare industry more generally. These forward-looking statements represent management's expectations, based ...

分组1 - Tenet Healthcare reported quarterly earnings of $4.7 per share, exceeding the Zacks Consensus Estimate of $4.08 per share, and up from $3.44 per share a year ago, representing an earnings surprise of +15.23% [1] - The company posted revenues of $5.53 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.38%, and an increase from $5.07 billion year-over-year [2] - Tenet has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 2.9% since the beginning of the year compared to the S&P 500's gain of 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $4.21 on revenues of $5.55 billion, and for the current fiscal year, it is $16.67 on revenues of $22.27 billion [7] - The Zacks Industry Rank for Medical - Hospital is currently in the bottom 14% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Core Insights - Tenet Healthcare Corporation reported strong financial results for the fourth quarter and full year 2025, with a net income of $371 million or $4.22 per diluted share in Q4 2025, reflecting a 16.7% increase from Q4 2024 [1][2] - Adjusted diluted earnings per share rose 36.6% to $4.70 in Q4 2025 compared to $3.44 in Q4 2024, driven by robust revenue growth and disciplined expense management [1][2] - The company anticipates FY 2026 Adjusted EBITDA to be between $4.485 billion and $4.785 billion, indicating continued growth expectations [1][2] Financial Performance - Q4 2025 net operating revenues reached $5.527 billion, up 8.9% from $5.073 billion in Q4 2024, while FY 2025 revenues totaled $21.310 billion, a 3.1% increase from $20.675 billion in FY 2024 [1][5] - Consolidated Adjusted EBITDA for Q4 2025 was $1.183 billion, a 12.9% increase from $1.048 billion in Q4 2024, with an Adjusted EBITDA margin of 21.4% [1][2] - The company generated free cash flow of $2.53 billion in FY 2025, compared to $1.116 billion in FY 2024, highlighting improved cash generation capabilities [1][5] Segment Performance - The Ambulatory Care segment reported Q4 2025 net operating revenues of $1.433 billion, a 13.8% increase from $1.259 billion in Q4 2024, driven by strong same-facility net patient service revenues [2][6] - The Hospital Operations segment saw Q4 2025 net operating revenues of $4.094 billion, a 7.3% increase from $3.814 billion in Q4 2024, attributed to favorable payer mix and higher acuity services [2][6] - Adjusted EBITDA for the Ambulatory segment was $580 million in Q4 2025, up 9.4% from $530 million in Q4 2024, while the Hospital segment's Adjusted EBITDA increased to $603 million from $518 million in the same period [2][6] Balance Sheet and Cash Flow - Cash flows from operating activities for FY 2025 were $3.54 billion, significantly higher than $2.047 billion in FY 2024, reflecting improved operational efficiency [1][5] - The company repurchased 8.8 million shares for $1.386 billion in FY 2025, indicating a commitment to returning value to shareholders [1][5] - As of December 31, 2025, the ratio of net debt to Adjusted EBITDA was 2.25x, down from 2.54x a year earlier, indicating improved leverage [1][5] 2026 Financial Outlook - For FY 2026, Tenet expects net operating revenues to be between $21.500 billion and $22.300 billion, with net income available to common stockholders projected between $2.605 billion and $2.840 billion [2][6] - The company anticipates Adjusted EBITDA margins to range from 20.9% to 21.5% in FY 2026, reflecting continued operational improvements [2][6] - The Ambulatory segment is expected to see net operating revenues of $5.500 billion to $5.700 billion, while the Hospital segment is projected to generate $16.000 billion to $16.600 billion in revenues [2][6]

Core Insights - Tenet Healthcare Corporation (THC) is scheduled to report its fourth-quarter 2025 results on February 11, 2026, with earnings estimated at $4.08 per share and revenues of $5.45 billion [1] Financial Performance Estimates - The fourth-quarter earnings estimate has increased by $0.03 over the past 60 days, indicating a year-over-year increase of 18.6% [2] - The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 7.5% [2] - For the full year 2025, the revenue estimate is $21.26 billion, reflecting a 2.9% year-over-year rise, while the earnings per share estimate is $16.15, indicating a 35.9% increase year-over-year [3] Earnings Prediction Model - The current model does not predict a definitive earnings beat for THC, as it has an Earnings ESP of +2.72% and a Zacks Rank of 4 (Sell) [4] Q4 Results Influencing Factors - THC is expected to report Q4 EPS of $4.08, up 18.6% year-over-year, with revenues projected to rise by 7.5% [7] - Hospital patient days and average length of stay are projected to decline sharply in Q4 [7] - The Ambulatory Care segment is anticipated to experience strong growth, with operating revenues expected to rise [7] - Adjusted patient admissions in total hospital operations are estimated to grow by 3.9% year-over-year, while adjusted patient admissions on the same hospital basis indicate a 2.7% increase [8] Ambulatory Care Segment Performance - The Ambulatory Care business is likely to benefit from improved patient volumes, new service line growth, and acquisitions, with operating revenues expected to grow by 8.4% year-over-year [9] - The consensus estimate for adjusted EBITDA from Ambulatory Care operations suggests a 9% year-over-year growth [9] Hospital Operations and Services - The Zacks Consensus Estimate for Hospital Operations and Services revenues for Q4 is $4.07 billion, indicating a 6.9% increase from the previous year [10] - The consensus mark for net patient revenues per adjusted admission signals a 4.5% year-over-year increase [10] Challenges and Cost Considerations - Despite expected growth, total hospital patient days are projected to decrease by 6.5% year-over-year, and the average length of stay is expected to decline by 8.8% [11][12] - Increased utilization is anticipated to lead to higher costs in Q4, making an earnings beat uncertain [12] Industry Comparisons - Other companies in the medical sector, such as HCA Healthcare, Ensign Group, and Encompass Health, have reported their Q4 results, with varying degrees of performance against consensus estimates [13][14][15]

Core Viewpoint - Tenet Healthcare announced an accretive transaction involving Conifer, indicating a strategic move to enhance its financial position and operational capabilities [2]. Group 1: Company Overview - Tenet Healthcare's management team participating in the call includes Dr. Saum Sutaria, Chairman and CEO, and Sun Park, Executive Vice President and CFO [2]. - The conference call is being recorded, suggesting a formal approach to investor communication [1]. Group 2: Financial Insights - The transaction is described as accretive, which implies that it is expected to increase earnings per share and overall financial performance for Tenet [2].

Tenet Healthcare Analyst Conference Call Summary Company Overview - **Company**: Tenet Healthcare (NYSE: THC) - **Date of Call**: February 02, 2026 - **Key Participants**: - Will McDowell, Vice President of Investor Relations - Saum Sutaria, Chairman and CEO - Sun Park, Executive Vice President and CFO Core Industry Insights - **Industry**: Healthcare, specifically focusing on revenue cycle management through Conifer, a subsidiary of Tenet Key Points and Arguments Financial Performance and Transactions - **Fourth Quarter 2025 Adjusted EBITDA**: Expected to be at the upper end of the previously provided guidance, driven by strong same-store revenues and disciplined expense management in hospitals and USPI [3] - **Conifer Transaction**: - Closed an asset sale regarding Conifer's Revenue Cycle Management Services contract with CommonSpirit valued at **$2.65 billion** [4] - Transaction includes cash payments, reduction of liabilities, and acquisition of an additional **23.8% equity stake** in Conifer [4] - Represents an approximate **14x multiple** on the impacted 2025 Adjusted EBITDA less NCI [4] Transaction Mechanics - **Revenue Cycle Services**: Conifer will continue to provide services to CommonSpirit through the end of 2026, maintaining expected adjusted EBITDA of approximately **$190 million** for 2025 [5][6] - **Financial Terms**: - CommonSpirit to pay **$1.9 billion** to Tenet over three years, with **$540 million** due in Q1 2026 [7] - Tenet will pay **$540 million** to CommonSpirit to redeem their equity stake, effective January 1, 2026 [8] - Anticipated reduction of **$100 million** in NCI expenses in 2026 due to the transaction [6] Strategic Control and Future Investments - **Strategic Control**: The transaction returns full strategic control of Conifer to Tenet, allowing for focused investments in automation and AI to enhance operational efficiency [10][11] - **Investment Focus**: Emphasis on offshoring, automation, and AI to reduce costs and improve service delivery [10][30] - **Capital Allocation**: Plans to deploy capital for shareholder value generation, including share repurchases and M&A in the ambulatory space [11][55] Market Position and Client Retention - **Client Service**: Conifer's client service remains strong, with expectations to onboard new clients and redeploy resources effectively [14] - **Market Competitiveness**: Investments in technology and automation are aimed at reducing the cost to collect, enhancing Conifer's competitive position in the marketplace [22][30] Future Outlook - **2026 and Beyond**: - Continued focus on managing the existing contract with CommonSpirit while planning for future growth opportunities [62] - Anticipated changes in EBITDA for 2027, with ongoing assessments of resource redeployment and operational efficiency [63][64] Additional Important Insights - **AI and Automation Strategy**: Investments are not solely AI-focused but include a mix of automation and advanced analytics to improve workflow efficiency and reduce costs [41][42] - **Long-term Contract**: The contract with CommonSpirit began in 2012 and was set to run through 2032, indicating a long-term relationship prior to the recent transaction [46] This summary encapsulates the key discussions and insights from the Tenet Healthcare Analyst Conference Call, highlighting the company's strategic maneuvers, financial performance, and future outlook in the healthcare industry.

Financial Performance Expectations - Tenet Healthcare Corporation expects its Adjusted EBITDA for the year ended December 31, 2025, to be at the upper end of the guidance range of $4.47 billion to $4.57 billion[4]. - Investors are cautioned that actual results may differ from preliminary estimates due to potential adjustments before finalizing financial information[5]. - The Company emphasizes that forward-looking statements are subject to uncertainties that could materially affect actual results[11]. Balance Sheet Changes - The Company anticipates a reduction of approximately $885 million in redeemable non-controlling interest and other liabilities on its balance sheet due to recent transactions[9]. - The Company will see an increase of approximately $305 million to its additional paid-in capital as a result of the recent agreements[9]. Agreements and Payments - An aggregate payment of $1.9 billion from CommonSpirit Health to the Company will be made in annual installments over the next three years, with $540 million already satisfied[8]. - The redemption of CommonSpirit Health's 23.8% equity interest in Conifer Health will result in a payment of $540 million to Conifer Health, effective January 1, 2026[8]. - The Company has entered into an Omnibus Agreement with Conifer Health Solutions and CommonSpirit Health, which includes the termination of a Master Services Agreement effective December 31, 2026[8].